Videos
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
January 14, 2021
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Podcast
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
January 14, 2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
January 14, 2021
Christopher Yasenchak, MD, discusses real-world adherence to NCCN guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Videos
Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice
January 14, 2021
Mitul Gandhi, MD, discusses results from a study exploring real-world data on patient and provider preferences of rituximab administration for NHL.
Conference Coverage
Efficacy, Safety, Cost of Outpatient Transplantation for Patients With MM
December 22, 2020
Findings from a single center study show that the outpatient setting is safe, effective, and reduces the total length of hospital stay and overall cost of transplant for adult patients with MM.
Conference Coverage
Comparative- and Cost-Effectiveness of Two Regimens for Relapsed/Refractory MM
December 21, 2020
A recent study assessed the comparative efficacy and cost-effectiveness of daratumumab plus pomalidomide and dexamethasone versus isatuximab plus pomalidomide and dexamethasone for relapsed/refractory MM.
Videos
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
December 21, 2020
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
December 20, 2020
Patrick Connor Johnson, MD, discusses results from a retrospective analysis evaluating HCRU and end-of-life outcomes in patients with hematologic malignancies receiving CAR-T therapy.
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
December 20, 2020
Robert Rifkin, MD, discusses results from the TOURMALINE-MM2 trial which compared ixazomib, lenalidomide, and dexamethasone (IRd) versus placebo-Rd for transplant-ineligible patients with newly diagnosed MM.
Conference Coverage
Pre-Transplant MRD Status Predicts PFS, OS in Patients With MCL
December 18, 2020
MRD status in peripheral blood or bone marrow prior to autoSCT is an early predictor of PFS and OS in younger patients with MCL.
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
December 17, 2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
December 17, 2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Videos
First-Line Ibrutinib Demonstrates Long-Term Efficacy in TP53-Mutated CLL
December 17, 2020
John Allan, MD, discusses results from analysis exploring the long-term efficacy of first-line ibrutinib in patients with CLL harboring TP53 mutations.
Conference Coverage
Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting
December 14, 2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Conference Coverage
Rituximab Monotherapy Extends TTNT vs Observation in Advanced FL
December 11, 2020
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Podcast
First-Line Ibrutinib Effective for CLL/SLL Irrespective of Cytogenetic or Mutational Risk Features
December 10, 2020
Jan Burger, MD, PhD, discusses an analysis of the RESONATE-2 and iLLUMINATE studies, which explored outcomes of first-line ibrutinib in patients with CLL/SLL and high-risk genomic features.
Conference Coverage
Cost-Effectiveness Comparison of BTK Inhibitors for MCL
December 10, 2020
Acalabrutinib is more cost-effective and associated with better clinical outcomes compared with ibrutinib and zanubrutinib for relapsed/refractory MCL.
Conference Coverage
Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL
December 09, 2020
Study finds higher risk of atrial fibrillation among patients treated with single-agent ibrutinib for CLL or SLL in the real-world setting than in clinical trials.
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
December 09, 2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing DRd to DPd for lenalidomide-exposed patients with relapsed/refractory MM at Mayo Clinic.
Conference Coverage
Adding Rituximab to Anthracycline-Based Chemotherapy Increases PFS, OS in FL
December 09, 2020
The addition of rituximab to anthracycline-based chemotherapy demonstrates improved PFS and OS in FL, according to a 35-year follow-up analysis.
Videos
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
December 09, 2020
Karl Kilgore, PhD, discusses study results comparing patient characteristics, treatments, costs, and OS between Medicare beneficiaries with LBCL who received transplantation versus those who did not.
Videos
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
December 09, 2020
Parameswaran Hari, MBBS, MD, discusses study results estimating the costs associated with CRS and neurotoxicity management for patients with relapsed/refractory MM who received CAR-T therapy in the KarMMa trial.
Conference Coverage
Emory MRD Decision Framework Saves Costs, Improves Health Outcomes in MM
December 08, 2020
A proposed MRD decision framework at Emory demonstrates cost savings and improved health outcomes for patients with MM initiating maintenance therapy.
Conference Coverage
Increased Use of Maintenance Therapy Following Transplantation for MM in US Clinical Practice
December 08, 2020
Use of maintenance therapy following autologous stem cell transplantation for MM has increased in routine clinical practice in the US and is associated with longer time to next treatment.
Videos
Daratumumab Plus RVd Continues to Demonstrate Improved Responses in MM
December 08, 2020
Peter Voorhees, MD, presents updated efficacy and safety results from the GRIFFIN study, following 12 months of maintenance therapy with lenalidomide or daratumumab plus lenalidomide, bortezomib, and dexamethasone (VRd) for patients with newly diagnosed MM.
Videos
Daratumumab Plus VCd Improves Responses in Newly Diagnosed AL Amyloidosis
December 07, 2020
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which show the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone (VCd) improved the rate of deep hematologic responses in patients with newly diagnosed light-chain (AL) amyloidosis.
Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
December 07, 2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
Conference Coverage
Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting
December 06, 2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Podcast
Real-World Outcomes of First-Line Ibrutinib vs Chemoimmunotherapy for CLL
December 06, 2020
Lori Leslie, MD, discusses results from a real-world study evaluating clinical outcomes in high-risk and non-high-risk CLL.
Conference Coverage
Polatuzumab Vedotin Plus Bendamustine-Rituximab Cost-Effective for DLBCL
December 06, 2020
Study results show polatuzumab vedotin plus bendamustine-rituximab is cost-effective in comparison to bendamustine-rituximab alone for relapsed/refractory DLBCL in the US.
Conference Coverage
Real-World Treatment Patterns, Health Care Resource Utilization, and Costs in CML
December 05, 2020
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
Videos
Belantamab Mafodotin Plus Bortezomib and Dexamethasone for Relapsed/Refractory MM
December 05, 2020
Robert Rifkin, MD, discusses the ongoing, phase 3 DREAMM-7 study exploring belantamab mafodotin in combination with bortezomib and dexamethasone for patients with relapsed/refractory MM.
Videos
Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM
December 05, 2020
Meletios Dimopoulos, MD, discusses results from the phase 3 APOLLO study, which compared subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone for relapsed/refractory MM.
Conference Coverage
Ibrutinib Dose Reductions and Discontinuations for CLL in Routine Practice vs Clinical Trials
December 04, 2020
Ibrutinib dose reductions and discontinuations due to adverse events are higher in routine clinical practice than in clinical trials, according to results from a study presented at the ASH Annual Meeting.
Conference Coverage
Watch and Wait vs Initial Treatment for Advanced FL
December 04, 2020
Study findings show patients with advanced FL who received initial treatment had better OS compared to those managed using watch and wait.
Conference Coverage
Treatment Sequencing Impact on Outcomes and Costs in Relapsed/Refractory FL
November 30, 2020
The use of 90 Y-ibritumomab tiuxetan in consolidation or second-line treatment of relapsed or refractory FL demonstrated desired patient outcomes at one of the lowest cost profiles.